oral covalent EGFR ex20ins mutant-selective inhibitor Ph. I for NSCLC with EGFR ex20ins mutations opt. from screen of TKI's for EGFR ex20ins selectivity First Disclosures, ACS Fall 2023 Scorpion Therapeutics, Boston, MA